Bicyclic Heterocycles Modulate Cannabinoid Receptor Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for appetite regulation and obesity lack effective and sustainable solutions, particularly in addressing metabolic disorders and substance abuse, with existing CB-1 antagonists showing limited long-term efficacy and side effects.
Innovation Solution
Development of compounds according to Formula I, which are CB-1 receptor modulators, including antagonists and inverse agonists, designed to regulate appetite and weight by targeting the CB-1 receptor, potentially combined with other therapeutic agents for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CB-1 antagonists are used for appetite regulation and weight loss, then body weight and appetite are reduced, but long-term efficacy is limited and side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of CB-1 antagonists through systematic variations in molecular substituents, ring systems, and functional groups. This optimization of molecular parameters enhances receptor selectivity and binding affinity, thereby improving long-term efficacy while reducing off-target side effects associated with earlier antagonists
2Duration of action of stationary object
If CB-1 receptor modulation is used to treat metabolic disorders and obesity, then appetite and body weight are reduced, but existing treatments show limited sustainability
Solution Approach 1:
The patent employs dynamics by designing compounds with optimized pharmacokinetic properties including improved metabolic stability, enhanced oral bioavailability, and sustained plasma concentrations. These dynamic optimizations ensure consistent therapeutic efficacy over extended treatment periods, addressing the sustainability limitations of previous CB-1 antagonists
Data Source
AI summary
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formulas I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas:including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein B, R1, R2, R3 and x are described herein.